Divya Srikumaran, MD
Ophthalmology · Baltimore, MDNPI 1992841399
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,960 of the $2,381 with a category attached, or 82.3%. Alcon accounts for 89.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $1,960 and has fallen 98.7% since, to $26 in 2025.
Across 10 payments — averaging $238.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Johnson & Johnson Surgical Vision, Inc.$182
- Rayner Intraocular Lenses Limited$53
- Dompe US, Inc.$27
Across 10 payments — averaging $3678.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$37K
What the payments were for
- Consulting fees$1,96082%
- Food & beverage$42118%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 3 | $2,118 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $182 |
| Rayner Intraocular Lenses Limited | 3 | $53 |
| Dompe US, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENUITY$1,960
- Hydrus Microstent$132
How this compares
$2,381 in reported general payments places this provider in the 65th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 17 | $27,364 |
| Prednisolone Acetate | 142 | $4,567 |
| Loteprednol Etabonate | 19 | $2,916 |
| Fluorometholone | 24 | $2,042 |
| ValacyclovirValacyclovir Hcl | 31 | $1,825 |
| Acyclovir | 15 | $1,038 |
| Timolol Maleate | 16 | $627 |
| Azithromycin | 45 | $282 |
| Ketorolac Tromethamine | 18 | $197 |
| ErythromycinErythromycin Base | 23 | $193 |
| Ofloxacin | 15 | $134 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $127 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Baltimore
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Neil BresslerBaltimore$265K
- Adrienne ScottBaltimore$170K
- Jennifer ThorneBaltimore$128K
- Earl CravenBaltimore$120K
- Peter CampochiaroBaltimore$103K
- Gail SchwartzBaltimore$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.